Finance

Beta
Lists
DMRA:NASDAQ
Damora Therapeutics Inc
$26.01
+7.43%
(+1.80) 1D
$26.01
0.00% (0.00)
After hours
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMRA...
Open
$24.46
High
$26.63
Low
$24.44
Mkt. cap
1.60B
Avg. vol.
703.26K
Volume
0.00
52-wk high
$29.22
52-wk low
$16.50
EPS
-$141.43
Beta
1.46
Shares outstanding
61.55M
No. of employees
7
Open
$24.46
High
$26.63
Low
$24.44
Mkt. cap
1.60B
Avg. vol.
703.26K
Volume
0.00
52-wk high
$29.22
52-wk low
$16.50
EPS
-$141.43
Beta
1.46
Shares outstanding
61.55M
No. of employees
7
News stories
From sources across the web
About Damora Therapeutics Inc
CEO-
Employees7
Founded2011
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedamoratx.com
Analyst ratings
Based on 7 analysts giving stock ratings to DMRA in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for DMRA in the last 3 months.
Highest
Current $26.01
$51.00 (+96.08%)
Average
$42.67 (+64.05%)
Lowest
$35.00 (+34.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
$40.00
+53.8%
06/30/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+73%
06/22/2026
David Nierengarten
Wedbush
Buy
Maintained
$35.00
+34.6%
06/16/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+53.8%
06/15/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Initiated
$45.00
+73%
06/11/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$51.00
+96.1%
05/15/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$46.00
+76.9%
03/25/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+73%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.46M
1.42M
23.32M
23.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.96M
1.74M
4.07M
7.03M
Operating expense
3.42M
3.16M
27.39M
30.81M
Total operating expenses
3.42M
3.16M
27.39M
30.81M
Operating income
-3.42M
-3.16M
-27.39M
-30.81M
Other non operating income
-
-
-
-
EBT including unusual items
-3.43M
-3.13M
-200.69M
-27.74M
EBT excluding unusual items
-3.43M
-3.13M
-26.38M
-27.74M
Income tax expense
4.00K
-
44.00K
42.00K
Effective tax rate
-0.12%
-
-0.02%
-0.15%
Other operating expenses
-
-
-
-
Net income
-3.44M
-3.13M
-200.74M
-27.78M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0.62
Interest and investment income
50.00K
42.00K
1.00M
3.07M
Interest expense
-
-
-
-
Net interest expenses
50.00K
42.00K
1.00M
3.07M
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.42M
-3.15M
-27.38M
-30.81M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer